Table 3.
Cumulative pathology for mice pre-treated intravaginally with curcumin nanoparticles and infected with high- or low-dose HSV-2.
| Pre-Treatment | HSV-2 Infection Dosage | Number of Mice | Days with No Pathology | Cumulative Pathology Score | Average Score per Mouse |
|---|---|---|---|---|---|
| Water | high | 4 | 1–3 | 75 | 18.8 |
| Vehicle-only Nanoparticles | high | 5 | 1–2 | 98 | 19.6 |
| Curcumin Nanoparticles | high | 6 | 1–3 | 95 | 15.8 |
| Vehicle-only Nanoparticles | low | 5 | 4–6 | 53 | 10.6 |
| Curcumin Nanoparticles | low | 5 | 4–6 | 53 | 10.6 |
Pre-treatment was 6 h prior to HSV-2 infection. Pathology was observed for 8 days for mice receiving IVAG high dose (104 PFU/mouse) and 10 days for those with low dose (103 PFU/mouse).